Patient Navigation Plus mHealth Incentives for Linkage to OUD Care for Adults Who Also Use Methamphetamines
4 affiliations
- 1Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle
- 2Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle
- 3Research and Data Analysis Division, Washington State Department of Social and Health Services, Olympia
- 4Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts
Abstract
Importance: Hospitalization is common among people with opioid use disorder (OUD) and is recognized as a reachable moment to start treatment. Methamphetamine use among people with OUD is associated with decreased linkage to postdischarge OUD care.
Objective: To determine the feasibility, acceptability, and exploratory clinical outcomes of a pilot randomized clinical trial (RCT) of an adherence-focused mobile health (mHealth) intervention aiming to increase linkage to and retention in outpatient buprenorphine services for patients hospitalized with OUD and methamphetamine use.
Design, Setting, and Participants: This single-site, 2-arm pilot RCT was conducted from January 3, 2024, to April 14, 2025, at a single-site, large urban safety net hospital in Seattle, Washington. Patients 18 years or older were eligible if they had initiated buprenorphine for OUD while in the hospital and had used methamphetamine within the past 30 days. Participants were randomized to the mHealth Incentivized Adherence Plus Patient Navigation (MIAPP) intervention or to treatment as usual (TAU).
Intervention: The MIAPP intervention combined financial incentives via mHealth-based adherence monitoring with a patient navigator (PN) during the first 30 days after discharge.
Main Outcomes and Measures: Feasibility was assessed by meeting the target enrollment of 40 participants and intervention delivery. Acceptability was measured by patient satisfaction ratings on a scale from 0 to 10, with 0 indicating not at all satisfied and 10 indicating extremely satisfied. The main pilot clinical outcome was linkage to outpatient OUD care within 30 days of hospital discharge, defined as medications for OUD being prescribed or dispensed. Other outcomes included retention in buprenorphine treatment and hospital readmissions at 90 days; past 30-day methamphetamine use was measured at the 30-day follow-up visit.
Results: The target enrollment of 40 participants (mean [SD] age, 43.4 [12.6] years) was met. Most participants (33 [82.5%]) were male. The intervention was allocated to 20 participants and delivered to 19 (95.0%); 20 participants received TAU. Participants reported being highly satisfied with the PN, with a mean (SD) patient satisfaction rating of 9.9 (0.3). Linkage to OUD care at 30 days occurred in 11 participants (55.0%) in the intervention arm compared with 10 (50.0%) in the TAU arm (risk ratio, 1.10; 95% CI, 0.61-1.99).
Conclusions and Relevance: In this pilot RCT of the MIAPP intervention, study procedures were feasible and acceptable. While no difference in linkage rates was noted in this pilot study, larger studies are needed to determine intervention effectiveness.
Trial Registration: ClinicalTrials.gov Identifier: NCT06027814
Related
- Patient Navigation Plus mHealth Incentives for Linkage to OUD Care for Adults Who Also Use Methamphetamines : A Pilot Randomized Clinical Trial
- From Measured Accuracy to Patient Outcome: Navigation in Total Hip Arthroplasty and Molecular Diagnosis of Periprosthetic Joint Infection: A Narrative Review
- Hepatitis C Micro-Elimination Through Patient Navigation of Individuals Experiencing Elevated Risk in a Mid-Atlantic Regional Healthcare System in 2022 and 2023: A Cohort Study.
- Provider-initiated screening clinical breast examination and patient navigation in sub-Saharan Africa: protocol for an implementation mapping-based pilot study.
- mHealth-based lifestyle intervention for hypertension in community-dwelling adults: a cluster-randomized controlled trial with exploratory multi-omics analyses
BibTeX
@article{bhatraju2026patient,
title = {{Patient Navigation Plus mHealth Incentives for Linkage to OUD Care for Adults Who Also Use Methamphetamines}},
author = {Elenore P. Bhatraju and Kaitlin A. Zinsli and Devin N. Kennedy and Alexander J. Gojic and Matthew Iles-Shih and Joseph O. Merrill and Elizabeth C. Speaker and Jeffrey H. Samet and Kevin A. Hallgren and Judith I. Tsui},
journal = {JAMA Network Open},
year = {2026},
month = oct,
doi = {10.1001/jamanetworkopen.2026.38542},
url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855264},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Patient Navigation Plus mHealth Incentives for Linkage to OUD Care for Adults Who Also Use Methamphetamines
AU - Elenore P. Bhatraju
AU - Kaitlin A. Zinsli
AU - Devin N. Kennedy
AU - Alexander J. Gojic
AU - Matthew Iles-Shih
AU - Joseph O. Merrill
AU - Elizabeth C. Speaker
AU - Jeffrey H. Samet
AU - Kevin A. Hallgren
AU - Judith I. Tsui
PY - 2026
DA - 2026/10/13
JO - JAMA Network Open
DO - 10.1001/jamanetworkopen.2026.38542
UR - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855264
AB - Importance: Hospitalization is common among people with opioid use disorder (OUD) and is recognized as a reachable moment to start treatment. Methamphetamine use among people with OUD is associated with decreased linkage to postdischarge OUD care. Objective: To determine the feasibility, acceptability, and exploratory clinical outcomes of a pilot randomized clinical trial (RCT) of an adherence-focused mobile health (mHealth) intervention aiming to increase linkage to and retention in outpatient buprenorphine services for patients hospitalized with OUD and methamphetamine use. Design, Setting, and Participants: This single-site, 2-arm pilot RCT was conducted from January 3, 2024, to April 14, 2025, at a single-site, large urban safety net hospital in Seattle, Washington. Patients 18 years or older were eligible if they had initiated buprenorphine for OUD while in the hospital and had used methamphetamine within the past 30 days. Participants were randomized to the mHealth Incentivized Adherence Plus Patient Navigation (MIAPP) intervention or to treatment as usual (TAU). Intervention: The MIAPP intervention combined financial incentives via mHealth-based adherence monitoring with a patient navigator (PN) during the first 30 days after discharge. Main Outcomes and Measures: Feasibility was assessed by meeting the target enrollment of 40 participants and intervention delivery. Acceptability was measured by patient satisfaction ratings on a scale from 0 to 10, with 0 indicating not at all satisfied and 10 indicating extremely satisfied. The main pilot clinical outcome was linkage to outpatient OUD care within 30 days of hospital discharge, defined as medications for OUD being prescribed or dispensed. Other outcomes included retention in buprenorphine treatment and hospital readmissions at 90 days; past 30-day methamphetamine use was measured at the 30-day follow-up visit. Results: The target enrollment of 40 participants (mean [SD] age, 43.4 [12.6] years) was met. Most participants (33 [82.5%]) were male. The intervention was allocated to 20 participants and delivered to 19 (95.0%); 20 participants received TAU. Participants reported being highly satisfied with the PN, with a mean (SD) patient satisfaction rating of 9.9 (0.3). Linkage to OUD care at 30 days occurred in 11 participants (55.0%) in the intervention arm compared with 10 (50.0%) in the TAU arm (risk ratio, 1.10; 95% CI, 0.61-1.99). Conclusions and Relevance: In this pilot RCT of the MIAPP intervention, study procedures were feasible and acceptable. While no difference in linkage rates was noted in this pilot study, larger studies are needed to determine intervention effectiveness. Trial Registration: ClinicalTrials.gov Identifier: NCT06027814
SN - 2574-3805
ER -